Table 1. Clinical characteristics of the 13 grafted patients tested for the presence of antibodies against foetal donors' HLA I antigens.

Patient	1	2	3	4	5	6	7	8	9	10	11	12	13
Disease duration (y)	11	8	5	6	9	9	7	7	7	5	4	4	6
TFC	10	10	11	11	9	7	10	13	8	9	10	12	13
UHDRS	55	61	28	36	37	64	32	23	64	26	50	28	15
MDRS	111	120	125	124	122	133	122	143	127	122	135	132	139
AC HLA I	−	+	+	+	+	−	−	−	−	−	+	−	−
Cyclosporin A (m)	9	13	9	9	6	7	7	7	ongoing	ongoing	6	6	ongoing
Imurel/solupred (m)	13	12	10	12	12	17	12	8	ongoing	ongoing	ongoing	12	ongoing
Adverse effects	−	sdh	Rejection	−	−	−	−	−	−	inf	−	sdh	−

Results of evaluation scales for general capacity (TFC, total functional capacitance), motor symptoms (UHDRS, motor part of the Unified Huntington Disease Rating Scale) and cognitive functions (MDRS, Mattis Dementia Rating Scale) are indicated at the time of grafting. The situation of the immunosuppressive treatment is indicated at the time of analysis of antibodies, either in months (m) when they have been interrupted according to the protocol (see text), or else as “ongoing”. Serious adverse effects besides rejection (patient 3, in bold) were subdural hematomas (sdh, in two cases) and cerebral infection (inf, 1 case). For sake of anonymity, individual patients' age, sex and number of CAG repeats are not shown. They were all between 39 and 55 years of age at the time of grafting; there were 5 women and 8 men; CAG repeats ranged between 42 and 49.